Double-Digit Drug Stock Movers (DXCM, CO, ALTH)
DexCom, Inc. (NASDAQ:DXCM) slumped 22% to $10.85 after the company posted a worse than expected Q3 loss and revenues that missed the Street’s estimate. The Company’s third fiscal quarter loss narrowed to $13.4 million or 23 cents a share from $13.5 million or 29 cents a share last year. Revenue rose 61 percent to $11.7 [...]
Double-Digit Drug Stock Movers (DXCM, CO, ALTH)
DexCom, Inc. (NASDAQ:DXCM) slumped 22% to $10.85 after the company posted a worse than expected Q3 loss and revenues that missed the Street’s estimate. The Company’s third fiscal quarter loss narrowed to $13.4 million or 23 cents a share from $13.5 million or 29 cents a share last year. Revenue rose 61 percent to $11.7 [...]
Double-Digit Drug Stock Movers (DXCM, CO, ALTH)
DexCom, Inc. (NASDAQ:DXCM) slumped 22% to $10.85 after the company posted a worse than expected Q3 loss and revenues that missed the Street’s estimate. The Company’s third fiscal quarter loss narrowed to $13.4 million or 23 cents a share from $13.5 million or 29 cents a share last year. Revenue rose 61 percent to $11.7 [...]
NASDAQ Stocks Declining (ALXA, CTXS, ALTH)
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) plunged 50.50% to $1.50 on about 4.37 million shares after it made its fresh 52-week low of $1.35. The company said the Food and Drug Administration declined to clear for marketing AZ-004, a potential treatment for agitation in patients with schizophrenia or bipolar disorder. In February, Valeant Pharmaceuticals licensed from Alexza [...]